	US 12,146,885 B2
	Biomarkers for diagnosing implant related risk of implant revision due to aseptic loosening
Stein Lian, Kvaloya (NO); Jarle Mikalsen, Tromsdalen (NO); Eric Bendiksen, Krokelvdalen (NO); and Anders Einung Hansen, Tromso (NO)
Assigned to Lyfstone B.V., Abcoude (NL)
Filed by LYFSTONE B.V., Abcoude (NO)
Filed on Dec. 16, 2022, as Appl. No. 18/067,622.
Application 18/067,622 is a continuation of application No. 17/812,537, filed on Jul. 14, 2022.
Application 17/812,537 is a continuation of application No. 16/483,784, granted, now 11,402,389, issued on Aug. 2, 2022, previously published as PCT/EP2018/053044, filed on Feb. 7, 2018.
Claims priority of application No. 20170185 (NO), filed on Feb. 7, 2017.
Prior Publication US 2023/0160910 A1, May 25, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/53 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/6887 (2013.01) [G01N 2333/4727 (2013.01); G01N 2800/108 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01)]

20 Claims

1. A method of treating a joint pathology, the method comprising:

detecting a level of calprotectin of at least 4 mg/l in a biological sample from a human subject, wherein the biological sample is synovial fluid collected at the site of a joint; and

administering to the human subject an anti-inflammatory drug therapy if the detected level of calprotectin is 4 mg/l to 50 mg/l, or administering joint surgery if the detected level of calprotectin is ≥50 mg/l;

wherein the calprotectin in the biological sample is a secreted polypeptide and not an intracellular polypeptide of intact cells present in the biological sample.